Last updated: June 9, 2026
PARNATE (Tranylcypromine) Suppliers: Who Manufactures and Supplies the Active Ingredient, Finished Drug, and Authorized Generics
PARNATE is a brand of tranylcypromine (a monoamine oxidase inhibitor, MAOI). Supply is constrained by a small number of finished-dose manufacturers and by limited availability of the active pharmaceutical ingredient (API) given the drug’s age and low market scale. For commercial planning, the key supplier set is the FDA “listed drugs” and distributors for NDCs on the Orange Book, plus the API and contract manufacturing (CMO) base used by the finished-dose holders.
No source data was provided identifying the specific PARNATE NDCs, Orange Book “listed drugs,” or current distributors by product strength and dosage form. Without those inputs, a complete and accurate supplier list cannot be produced.
What suppliers manufacture PARNATE tranylcypromine tablets and who holds the NDC?
To identify “suppliers” for PARNATE in a litigation- and launch-ready way, the reference points are:
- FDA Orange Book “listed drug” entry for tranylcypromine (PARNATE), including:
- applicant/holder
- dosage form and strength
- patent linkage status
- marketing status
- NDC labeler and listed manufacturer on the package and FDA registration records
- Wholesaler/distributor channels that carry the specific NDCs
Without the relevant Orange Book/NDC identifiers, any named “supplier” list would risk listing incorrect manufacturers for the wrong strength, dosage form, or labeler revision.
Which active ingredient tranylcypromine (API) manufacturers supply PARNATE?
API sourcing typically maps to:
- registered API manufacturers for tranylcypromine in FDA systems
- DMFs tied to the finished-dose holder
- CMO production contracts (not always publicly attributable)
No API supplier names can be asserted without a specific Orange Book/DMF-to-holder mapping for the currently marketed PARNATE entries.
Who are the contract manufacturers or labelers for current PARNATE supply?
Finished-dose production suppliers can differ by:
- tablet strength
- packaging configuration
- changes in labeler over time
Accurate mapping requires the currently marketed NDCs and their labeler/manufacturing sites as listed in FDA registration and labeling.
Are there authorized generic or branded-equivalent suppliers for PARNATE?
Whether there are:
- AB-rated products (authorized generic)
- pharmacy-distributed generics
- multiple brand holders with the same API
depends on the Orange Book “drug product” and “applicant” entries. Without NDC/Orange Book identification, the authorized generic landscape cannot be correctly enumerated.
Commercial supply implications for PARNATE
PARNATE is historically a niche MAOI with:
- restricted substitution in clinical practice
- potential wholesaler allocation during production or regulatory interruptions
- higher operational risk around single-site manufacturing and aging product portfolios
A supplier inventory is therefore most valuable when it is:
- NDC-specific
- time-stamped to the current marketing authorization
- tied to regulatory status (listed drug vs discontinued)
No time-stamped supplier inventory can be generated from the information provided.
Key Takeaways
- “Suppliers for PARNATE” must be defined by NDC-specific finished-dose manufacturers/labelers and, if needed, API/DMF-linked API sources.
- A correct supplier list requires Orange Book and NDC identifiers for the currently marketed PARNATE products.
- Without those identifiers, naming specific suppliers would not meet a high-stakes patent, regulatory, and supply-chain standard.
FAQs
- How do I find the current manufacturer for a specific PARNATE NDC?
- What is the difference between Orange Book “applicant/holder” and the physical manufacturer listed on labeling?
- How can DMF-linked tranylcypromine API suppliers be mapped to finished-dose holders?
- What causes PARNATE supply interruptions and how do suppliers change during labeling updates?
- Do PARNATE generics or authorized equivalents carry the same supplier base as the brand?
References
No sources were provided in the prompt.
